ArticleJournal of cancer survivorship : research and practice2026
Effects of the right to be forgotten for childhood or breast cancer survivors: results of a quasi-experimental study in France.
Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interventions to Reduce Financial Toxicity of Childhood, Adolescent, and Young Adult Cancer Survivors: A Scoping Review.Pediatric blood & cancer · 2026Article
- EBCC-15 manifesto: Removing age-related barriers to improve equity in breast cancer care.Breast (Edinburgh, Scotland) · 2026Review
- The right to be forgotten and workers' health protection: a critical balancing act.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeCancer survivors have reported difficulties in accessing loan-related insurance, in particular for a home loan. In France, a law called "the Right To Be Forgotten" (RTBF) was adopted in 2017 to counter this "financial toxicity" of cancer. Since then, eight other European countries have adopted or implemented legislation inspired by the French RTBF. Several patients' organizations in Europe have called for an extension of the RTBF across all European countries. The aim of this study was to evaluate the effects of the RTBF on the reduction of survivors experiencing difficulties in obtaining loan-related insurance after cancer in France.
methodA quasi-experimental study was conducted using different sources of recruitment to enroll breast and childhood cancer survivors (cases) and individuals without a history of cancer (controls). Difficulties in accessing loan-related insurance reported by cancer survivors and controls before and after the adoption of the law (2010-2022) were collected using an online questionnaire and compared between groups. Groups were matched using propensity scores on age, sex, the amount of insured capital, and health-related variables. The effect of the RTBF's adoption was estimated using a conditional logistic regression.
resultsOut of 552 matched respondents (1:3 case-control ratio), difficulties in accessing loan-related insurance were reported by 65% of cases vs. 16% of controls before the RTBF and by 35% of cases vs. 15% of controls after the RTBF (P < .0001). The likelihood of experiencing difficulties in obtaining a loan was significantly decreased (β = - 0.29; OR = 0.74; P = 0.01) after the RTBF. In subgroup analyses, the results remained significant solely for childhood cancer survivors.
conclusionsDespite a significant decrease in the proportion of cancer survivors experiencing difficulties after the adoption of the RTBF, there are possible difficulties in the law's implementation, dissemination, and usage, in particular for adult cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS: The RTBF may alleviate cancer survivors' difficulties in accessing loan-related insurance with a possible impact in decreasing the financial toxicity of cancer, both from a subjective and an objective point of view.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.